Company intelligence / Profile preview

Cango

Shanghai, Shanghai, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Cango Bio is a clinical-stage biopharmaceutical company specializing in the development of mRNA-based vaccines and therapeutics. Founded in 2021 by industry veterans, the company leverages a proprietary mRNA-LNP (lipid nanoparticle) platform to address infectious diseases and oncology. Its lead programs include mRNA vaccines for COVID-19, respiratory syncytial virus (RSV), and seasonal influenza. Cango Bio aims to optimize mRNA stability and delivery efficiency to create next-generation biologics with improved safety and efficacy profiles. The company is backed by prominent investors including Hillhouse Capital and IDG Capital.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsVaccineLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Cango.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cango.

Explore the full profile